Funding transnational collaborative research through joint transnational calls is one of the major objectives of E-Rare. This is the most important and effective joint activity to enhance the cooperation between European scientists working on rare diseases and thus reducing the fragmentation of research in this field. E-Rare launches calls on a yearly basis. The topic and eligibility criteria are specified every year and therefore may vary from one call to the other.

Germany
Italy
The Netherlands
EuPAPNet
European pulmonary alveolar proteinosis network : molecular determinants of causes, variability and outcome

Project Coordinator

Fondazione IRCCS Policlinico San Matteo Clina Malattie Apparato Respratiorio
Pavia
Italy

Partners

Jan C. Grutters St Antionius Hospital Department of Pulmonology Nieuwegein, The Netherlands
Matthias Griese University of Munich Children's Hospital Munich, Germany
Ulrich Costabel Ruhrlandklinik Abteilung Pneumologie/Allergologie Essen, Germany

Pulmonary Alveolar Proteinosis (PAP) is a neglected respiratory disorder. This project is aimed at creating, for the first time, a network for PAP among four centers from three countries (Italy, Germany and the Netherlands) with special interest in this disease. Three centers have skill in management of adult cases and one in pediatric cases of PAP. Major aims of the project will be to establish a database to include retrospectively and prospectively cases of PAP. Based on cohorts already available in the centers, we expect to enrol one of the largest series of PAP patients ever reported. We expect to understand more about the epidemiology of the different forms of PAP in Europe. We will also collect biomaterials form PAP patients (genomic DNA, blood and BAL cell mRNA, serum) to perform genome-wide and transcriptomic analysis, as well as candidate gene and targeted biochemical investigations, to create a library of biomarkers, putatively predicting the natural history of the disease, aand the clinical course following whole lung lavage (WLL), which is the current standard of care of PAP. Molecular and biochemical data obtained will provide information on the pathogenesis of the disorder, such as gene/ gene product acting as modifiers of the clinical course. Finally, the outcome of the disorder will be evaluated in function of the different WLL techniques, to establish the optimal methodology. The transnational collaboration planned in the present project is a unique opportunity to translate basic information into the clinical assessment and management of PAP.

E-Rare 2012 - Created by Toussaint Biger